The potential role of 68ga-labeled peptides in pet imaging of infection

Nuclear Medicine Communications

Volumn 29, Issue 8, 2008, Pages 663-665

  Sathekge, Mike ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; DIAGNOSTIC AGENT; GADOLINIUM; PEPTIDE; RADIOISOTOPE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GALLIUM 68; MOLYBDENUM 99; TECHNETIUM 99M;

ANIMAL; BACTERIAL INFECTION; EDITORIAL; HUMAN; MYCOSIS; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; CANDIDA ALBICANS; EXTRAPULMONARY TUBERCULOSIS; HALF LIFE TIME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; ISOTOPE LABELING; MULTIDRUG RESISTANT TUBERCULOSIS; TUBERCULOSIS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; GADOLINIUM; HUMANS; MYCOSES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES;

EID: 55249098401     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32830160fd     Document Type: Editorial

References (30)

1. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46:172S-178S.
2. Deutsch E. Clinical PET: its time has come? J Nucl Med 1993; 34:1132-1133.
3. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-1757.
4. 68Gallium-DOTA-Tyr(3)-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Nucl Med 2007; 48:508-518.
5. 68Ga-labeled bombesin(6-14) analog. J Nucl Med 2005;46:691-699.
6. 4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999; 83:657-663.
7. 68Ga. Eur J Nucl Med Mol Imaging 2005; 32:478-485.
8. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 2006; 12:3843-3850.
9. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 2003; 30:1134-1139.
10. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002; 32:97-109.
11. 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005; 46:1881-1888.
12. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995; 36:623-627.
13. Fischman AJ, Rauh D, Solomon H, Babich JW, Tompkins RG, Kroon D, in vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. J Nucl Med 1993; 34:2130-2134.
14. Ganz ME, Lehrer RI. Defensins and other endogenous peptide antibiotics of the vertebrates. J Leukocyte Biol 1995; 58:128-136.
15. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999; 1462:11-28.
16. Lupetti A, Nibbering PH, Welling MM, Pauwels EKJ. Radiopharmaceuticals: new antimicrobial agents. Trends Biotech 2003; 21:70-73.
17. Hiemstra PS, Van den Barselaar MT, Roest M, Nibbering PH, van Furth R. Ubiquicidin, a novel murine microbicidal protein in the cytosolic fraction of the activated macrophages. J Leukocyte Biol 1999; 66:423-428.
18. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 2001; 42:788-794.
19. 99mTc-UBI specificity for bacteria. Nucl Med Biol 2003; 30:597-603.
20. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72:1-3.
21. Global Tuberculosis Control: WHO Report 2004.
22. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, et al. Infections with mycobacterium tuberculosis and mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-872.
23. O’Doherty MJ, Nunan TO. Nuclear medicine and AIDS. Nucl Med Commun 1993; 14:830-848.
24. Plas DR, Rathmell JC, Thompson CB. Homeostatic control of lymphocyte revival: potential origins and implications. Nat Immunol 2002; 3:515-521.
25. Liu RS, Shei HR, Chu YK, Feng CF, Su WJ. Detection of extrapulmonary tuberculosis with F-18 FDG PET. Rev Med Nucl Alasbinm J 2002; 17:504.
26. Miceli M, Atoui R, Walker R, Mahfouz T, Mirza N, Diaz J, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol 2004; 22:1949-1956.
27. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 2005; 23:7857-7863.
28. De Winter F, Vogelaers D, Gemmel F, Dierckx RA. Promising role of 18-F-flouro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002; 21:247-257.
29. Mäkinen TJ, Lankinen P, Pöyhönen T, Jalava J, Aro HT, Roivainen A. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging 2005; 32:1259-1268.
30. Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 2007; 34:1897-1901.